Literature DB >> 3016896

Psychotomimesis mediated by kappa opiate receptors.

A Pfeiffer, V Brantl, A Herz, H M Emrich.   

Abstract

The kappa opioid agonists are analgesics that seem to be free of undesired morphine-like effects. Their dysphoric actions observed with the kappa agonist cyclazocine are thought to be mediated by an action at sigma-phencyclidine receptors. The benzomorphan kappa agonist MR 2033 is inactive at sigma-phencyclidine receptors. In male subjects, the opiate-active (-)-isomer, but not the (+)-isomer, elicited dose-dependent dysphoric and psychotomimetic effects that were antagonized by naloxone. Thus, kappa opiate receptors seem to mediate psychotomimetic effects. In view of the euphorigenic properties of mu agonists, our results imply the existence of opposed opioid systems affecting emotional and perceptual experiences.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3016896     DOI: 10.1126/science.3016896

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  300 in total

Review 1.  Neural systems underlying opiate addiction.

Authors:  Taco J De Vries; Toni S Shippenberg
Journal:  J Neurosci       Date:  2002-05-01       Impact factor: 6.167

Review 2.  The dynorphin/κ-opioid receptor system and its role in psychiatric disorders.

Authors:  H A Tejeda; T S Shippenberg; R Henriksson
Journal:  Cell Mol Life Sci       Date:  2011-10-16       Impact factor: 9.261

3.  Selective p38α MAPK deletion in serotonergic neurons produces stress resilience in models of depression and addiction.

Authors:  Michael R Bruchas; Abigail G Schindler; Haripriya Shankar; Daniel I Messinger; Mayumi Miyatake; Benjamin B Land; Julia C Lemos; Catherine E Hagan; John F Neumaier; Albert Quintana; Richard D Palmiter; Charles Chavkin
Journal:  Neuron       Date:  2011-08-11       Impact factor: 17.173

4.  Tracking down the molecular substrates of stress: new roles for p38α MAPK and kappa-opioid receptors.

Authors:  John W Muschamp; Ashlee Van't Veer; William A Carlezon
Journal:  Neuron       Date:  2011-08-11       Impact factor: 17.173

Review 5.  The role of kappa-opioid receptor activation in mediating antinociception and addiction.

Authors:  Yu-hua Wang; Jian-feng Sun; Yi-min Tao; Zhi-qiang Chi; Jing-gen Liu
Journal:  Acta Pharmacol Sin       Date:  2010-08-23       Impact factor: 6.150

6.  Role of the kappa-opioid receptor system in stress-induced reinstatement of nicotine seeking in rats.

Authors:  Stephanie L Grella; Douglas Funk; Kathy Coen; Zhaoxia Li; A D Lê
Journal:  Behav Brain Res       Date:  2014-02-28       Impact factor: 3.332

Review 7.  Targeting opioid dysregulation in depression for the development of novel therapeutics.

Authors:  Caroline A Browne; Irwin Lucki
Journal:  Pharmacol Ther       Date:  2019-04-30       Impact factor: 12.310

8.  Translation of structure-activity relationships from cyclic mixed efficacy opioid peptides to linear analogues.

Authors:  Jessica P Anand; Vanessa R Porter-Barrus; Helen V Waldschmidt; Larisa Yeomans; Irina D Pogozheva; John R Traynor; Henry I Mosberg
Journal:  Biopolymers       Date:  2014-01       Impact factor: 2.505

Review 9.  Kappa-Opioid Antagonists for Psychiatric Disorders: From Bench to Clinical Trials.

Authors:  William A Carlezon; Andrew D Krystal
Journal:  Depress Anxiety       Date:  2016-10       Impact factor: 6.505

10.  The effects of morphine, naloxone, and κ opioid manipulation on endocrine functioning and social behavior in monogamous titi monkeys (Callicebus cupreus).

Authors:  B J Ragen; N Maninger; S P Mendoza; K L Bales
Journal:  Neuroscience       Date:  2014-12-06       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.